US/UK/Canada

Share

Contacts

  • Orexo
    Box 303 751 05 Uppsala
    +46 (0)18 780 88 00
    +46 (0)18 780 88 88
    http://www.orexo.com

    • Quotes

    With the acquisition of the rights to two digital health products from GAIA and the appointment of Dennis, a thought leader in the digital health industry in the US, we are well positioned to lead this development within the complementary disease areas of our pharmaceutical business.
    Nikolaj Sørensen, President and CEO
    Our strategy is to focus on solutions with scientifically proven therapeutic effect which will benefit the healthcare system as a whole and more importantly patients.
    Nikolaj Sørensen, CEO, about Digital Therapies
    I am convinced that DTx will become an integral and natural part of addiction treatment in the future. This digital therapy for OUD patients is perfectly positioned with Orexo’s competences and commercial organization in the US.
    Nikolaj Sørensen, President and CEO
    Mundipharma Australia has been a good partner in the approval process and we are confident that their experience and infrastructure will create a strong foundation for a successful launch of Zubsolv®
    Nikolaj Sørensen, President and CEO
    Pick a time period -
    Tags ( Active)

    Q4 incl. Full Year Report 2019

    Strong fundamentals in place to fuel strategy for future growth Q4 2019 highlights · Total net revenues of SEK 238.1 million (227.1), up 4.8 percent · Zubsolv® US net revenues of SEK 190.5 million (166.7), up 14.3 percent in SEK and 7.5 percent in local currency · Net earnings of SEK 38.9 million (51.6), down 24.6 percent · EBITDA of SEK 85.8 million (42.8), up 100.5 percent. EBITDA ex Abstral® of SEK 39.6 million (-9.6). · US EBIT of SEK 98.2 million (62.0), up 58,4 percent · Cash flow from operating activities of SEK 60.2 million (71.7), building a cash balance of

    Save the date: Orexo to host Capital Markets Day focusing on Digital Health, on March 17, 2020

    Uppsala, Sweden – December 3, 2019 – Orexo AB (publ.), the fully integrated specialty pharmaceutical company with the aim of becoming a leader in the treatment of addiction, today announces that the company will host a Capital Markets Day for investors, analysts and media in Stockholm, Sweden, on March 17, 2020. Members of the management team, including Dennis Urbaniak recently appointed as EVP Digital Health, will provide an update on the company´s strategy, R&D pipeline and the business opportunities within Digital Health. External speaker will be Dr. Mario Weiss, CEO and founder of

    Orexo appoints Dennis Urbaniak as Executive Vice President Digital Health

    · Appointment strengthens Orexo’s competencies and resources within digital health · Orexo committed to finding innovative solutions to improve treatment of addiction Uppsala, Sweden – December 2, 2019. Orexo AB (publ), the fully integrated specialty pharmaceutical company with the aim of becoming a leader within treatment of addiction, today announces it has appointed Dennis Urbaniak as Executive Vice President (EVP) of Digital Health, effective today. Dennis will lead the establishment of Orexo’s global digital health business, initially through the development of two digital

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media